Published in Gene on April 29, 1997
Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. J Virol (1999) 2.49
The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J (2001) 2.16
Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J (2001) 2.10
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Sindbis virus vectors designed to express a foreign protein as a cleavable component of the viral structural polyprotein. J Virol (2003) 1.12
Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol (2002) 1.06
MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol (2005) 1.00
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine (2006) 0.99
A novel self-replicating chimeric lentivirus-like particle. J Virol (2011) 0.76
Recent care of common mental disorders in the United States : prevalence and conformance with evidence-based recommendations. J Gen Intern Med (2000) 4.63
Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry (1999) 2.97
Spike protein-nucleocapsid interactions drive the budding of alphaviruses. J Virol (1992) 2.91
Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry. J Cell Biol (1992) 2.26
Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) (1993) 2.20
Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 2.20
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
Aromatic interactions define the binding of the alphavirus spike to its nucleocapsid. Structure (1996) 2.12
A tyrosine-based motif in the cytoplasmic domain of the alphavirus envelope protein is essential for budding. EMBO J (1994) 2.09
Nuclear localization of Semliki Forest virus-specific nonstructural protein nsP2. J Virol (1990) 1.99
Cosmid cloning and transposon mutagenesis in Salmonella typhimurium using phage lambda vehicles. Mol Gen Genet (1981) 1.80
Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol (1999) 1.69
Assembly and entry mechanisms of Semliki Forest virus. Arch Virol Suppl (1994) 1.42
The signal sequence of the p62 protein of Semliki Forest virus is involved in initiation but not in completing chain translocation. J Cell Biol (1990) 1.38
Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry (1998) 1.38
Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther (2004) 1.36
Expression of heterologous proteins in cultured rat hippocampal neurons using the Semliki Forest virus vector. J Neurosci Res (1993) 1.34
Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut (2005) 1.33
Membrane protein lateral interactions control Semliki Forest virus budding. EMBO J (1994) 1.31
Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 1.30
In vivo transfer of chromosomal mutations onto multicopy plasmids by transduction with bacteriophage P1. Gene (1985) 1.26
The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. J Virol (1995) 1.26
High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system. Eur J Biochem (1994) 1.25
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A (1995) 1.21
Fate of the 6K membrane protein of Semliki Forest virus during virus assembly. Virology (1991) 1.20
Nucleotide sequence of the melA gene, coding for alpha-galactosidase in Escherichia coli K-12. Nucleic Acids Res (1987) 1.18
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16
Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol (2000) 1.15
Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther (2003) 1.11
Cloning of the regulatory locus ompB of Salmonella typhimurium LT-2. II. Identification of the envZ gene product, a protein involved in the expression of the porin proteins. Mol Gen Genet (1982) 1.10
Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol (2001) 1.09
Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther (1999) 1.07
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis (2001) 1.07
Alphavirus assembly and entry: role of the cytoplasmic tail of the E1 spike subunit. J Virol (1992) 1.07
Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses (1993) 1.07
Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem (1993) 1.04
The molecular pathogenesis of Semliki Forest virus: a model virus made useful? J Gen Virol (1999) 1.02
The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem (1991) 0.99
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine (1999) 0.99
Two mutations in the envelope glycoprotein E2 of Semliki Forest virus affecting the maturation and entry patterns of the virus alter pathogenicity for mice. Virology (1991) 0.98
A single amino acid change in the E2 spike protein of a virulent strain of Semliki Forest virus attenuates pathogenicity. J Gen Virol (1994) 0.94
Budding of enveloped viruses from the plasma membrane. Bioessays (1997) 0.93
Isolation and characterization of a substitution mutation in the ompR gene of Salmonella typhimurium LT2. J Bacteriol (1987) 0.91
Role of the C-terminal tryptophan residue for the structure-function of the alphavirus capsid protein. J Mol Biol (1998) 0.91
Expression of exogenous proteins in mammalian cells with the Semliki Forest virus vector. Methods Cell Biol (1994) 0.90
Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther (1999) 0.88
Suppressors of cleavage-site mutations in the p62 envelope protein of Semliki Forest virus reveal dynamics in spike structure and function. J Virol (1998) 0.88
M-X-I motif of semliki forest virus capsid protein affects nucleocapsid assembly. J Virol (2001) 0.88
Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. FEMS Immunol Med Microbiol (2000) 0.88
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol (1999) 0.87
Somatic cell hybrid panel and NotI linking clones for physical mapping of human chromosome 3. Genomics (1994) 0.86
The construction of a yeast artificial chromosome (YAC) contig in the vicinity of the Usher syndrome type IIa (USH2A) gene in 1q41. Genomics (1996) 0.86
Lipases from Rhizomucor miehei and Humicola lanuginosa: modification of the lid covering the active site alters enantioselectivity. J Protein Chem (1993) 0.86
Cloning of the regulatory locus ompB of Salmonella typhimurium LT-2. I. Isolation of the ompR gene and identification of its gene product. Mol Gen Genet (1982) 0.86
A conserved leucine in the cytoplasmic domain of the Semliki Forest virus spike protein is important for budding. Arch Virol (2000) 0.84
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol (2000) 0.83
A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine (2001) 0.83
Alphaviruses as vectors for gene delivery. Trends Biotechnol (1996) 0.82
Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine (2001) 0.82
Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Mol Biotechnol (1996) 0.81
An anti-HIV strategy combining chemotherapy and therapeutic vaccination. J Med Primatol (1999) 0.80
Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol (2002) 0.80
Early diagnosis of enteroviral meningitis by a solid-phase reverse immunosorbent test and virus isolation. Scand J Infect Dis (1990) 0.79
Alu-PCR approach to isolating NotI-linking clones from the 3p14-p21 region frequently deleted in renal cell carcinoma. Genomics (1993) 0.79
A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J Med Primatol (2000) 0.77
Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand J Immunol (2001) 0.77
Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Ther (1997) 0.77
Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther (2001) 0.77
Simple setup for rapid testing of third-order nonlinear optical materials. Appl Opt (1990) 0.75
Site-directed mutagenesis combined with chemical modification as a strategy for altering the specificity of the S1 and S1' pockets of subtilisin Bacillus lentus. Biochemistry (1998) 0.75
The SFV Gene Expression System. Methods Mol Med (1998) 0.75
Creation of a synthetically useful lipase with higher than wild-type enantioselectivity and maintained catalytic activity. Org Lett (1999) 0.75
[Cooperative project. Fewer sick days when health services and insurance fund work together]. Vardfacket (1992) 0.75
Construction and characterization of a NotI linking library from human chromosome region 1q25-qter. Genomics (1995) 0.75
First measurement of the transverse spin asymmetries of the deuteron in semi-inclusive deep inelastic scattering. Phys Rev Lett (2005) 0.75
[More effective cooperation reduces the need of sick-listing for musculoskeletal disorders]. Lakartidningen (1991) 0.75
[Can the chronically ill become the chronically healthy?]. Nord Med (1992) 0.75